{
    "clinical_study": {
        "@rank": "38626", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "ABT-450/r and ABT-530 co-administered with ribavirin (RBV) for 12 weeks"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "ABT-450/r and ABT-530 co-administered for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and antiviral effect of multiple doses\n      of ABT-450/r and ABT-530 coadministered with and without Ribavirin in adults with genotype 3\n      HCV infection."
        }, 
        "brief_title": "A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Hepatitis C", 
            "Hepatitis C Virus"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female (of non-child bearing potential) between 18 and 70 years of age with\n             Body Mass Index \u226518 to <38 kg/m2.\n\n          -  Chronic HCV genotype 3 infection prior to study enrollment and has never received\n             antiviral treatment for HCV.\n\n          -  Subject has plasma HCV RNA level > 10,000 IU/mL at Screening.\n\n          -  Sexually active males must be sterile, have male partners only, or agree to use two\n             effective forms of birth control for 7 months after stopping study drug.\n\n        Exclusion Criteria:\n\n          -  History of severe, life-threatening or other significant sensitivity to any drug.\n\n          -  Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human\n             Immunodeficiency virus antibody (HIV Ab).\n\n          -  Prior therapy for the treatment of HCV.\n\n          -  Any current or past clinical evidence of cirrhosis.\n\n          -  Any cause of liver disease other than chronic HCV-infection.\n\n          -  HCV genotype co-infection with any other HCV genotype.\n\n          -  Use of contraindicated medications within 2 weeks or 10 half-lives of dosing."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02068222", 
            "org_study_id": "M14-213"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 1", 
                    "Arm 2"
                ], 
                "description": "Tablet", 
                "intervention_name": "ABT-450/r", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm 1", 
                    "Arm 2"
                ], 
                "description": "Tablet", 
                "intervention_name": "ABT-530", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 1", 
                "description": "Tablet", 
                "intervention_name": "Ribavirin (RBV)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antiviral Agents", 
                "Ribavirin", 
                "Ritonavir"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic Hepatitis C", 
            "Hepatitis C virus", 
            "Interferon Free", 
            "Hepatitis C Genotype 3", 
            "Hepatitis C", 
            "HCV"
        ], 
        "lastchanged_date": "April 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Dothan", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "36305"
                    }, 
                    "name": "Site Reference ID/Investigator# 124035"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 124035", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78215"
                    }, 
                    "name": "Site Reference ID/Investigator# 124037"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 124037", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98104"
                    }, 
                    "name": "Site Reference ID/Investigator# 124036"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 124036", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-Label Pilot Study to Evaluate the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-530, With and Without Ribavirin (RBV) in Treatment-Na\u00efve Subjects With Genotype 3 Chronic Hepatitis C Virus (HCV) Infection", 
        "overall_contact": {
            "email": "charles.e.meyer@abbvie.com", 
            "last_name": "Charles E Meyer, BS", 
            "phone": "(847) 938-6564"
        }, 
        "overall_contact_backup": {
            "email": "traci.baker@abbvie.com", 
            "last_name": "Traci  Baker, MS", 
            "phone": "(847) 936-6555"
        }, 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Arman  Asatryan, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Hepatitis C virus ribonucleic acid less than the lower limit of quantification", 
            "measure": "The percentage of subjects who achieve 12-week sustained virologic response (SVR12) in each treatment arm", 
            "safety_issue": "No", 
            "time_frame": "12 weeks after last dose of study drug"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02068222"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Hepatitis C virus ribonucleic acid less than the lower limit of quantification", 
                "measure": "The percentage of subjects who achieve 24-week sustained virologic response (SVR24) in each treatment arm", 
                "safety_issue": "No", 
                "time_frame": "24 weeks after last dose of study drug"
            }, 
            {
                "description": "Percentage of subjects with quantifiable hepatitis C virus ribonucleic acid throughout the entire treatment period, confirmed quantifiable hepatitis C virus ribonucleic acid after previously having unquantifiable hepatitis C virus ribonucleic acid, or a confirmed increase of at least one log10 in hepatitis C virus ribonucleic acid during treatment", 
                "measure": "The percentage of subjects with virologic failure during treatment", 
                "safety_issue": "No", 
                "time_frame": "Up to Treatment Week 12"
            }, 
            {
                "description": "Percentage of subjects with confirmed quantifiable hepatitis C virus ribonucleic acid among subjects with unquantifiable hepatitis C virus ribonucleic acid at the end of treatment", 
                "measure": "The percentage of subjects with Post-Treatment relapse", 
                "safety_issue": "No", 
                "time_frame": "Within 12 weeks after the last dose of study drug"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}